(J.K. Anderson also Published as J.K. Hess-Wilson)
Bowles, K.C., Anderson, J.K., Anderson, R., Bani, B., Barnes, C.M., Brusseau, M., Cousins, I.T., Cushing, P., DiGuiseppi, B., Gray, B. and Higgins, C.P., 2024. Implications of grouping per-and polyfluoroalkyl substances for contaminated site regulation. Remediation Journal, 34(3), p.e21783.
Anderson, J.K., Schneider, D., Knutson, M. and Puchacz, Z., 2023. PFAS Source Differentiation Guide for Airports (No. ACRP Project 02-91). National Academies of Sciences, Engineering, and Medicine, Washington, DC: The National Academies Press. https://doi.org/10.17226/27164
Lafranconi, M., Anderson, J., Budinsky, R., Corey, L., Forsberg, N., Klapacz, J. and LeBaron, M.J., 2023. An integrated assessment of the 1, 4-dioxane cancer mode of action and threshold response in rodents. Regulatory Toxicology and Pharmacology, p.105428
Garvey, G.J., Anderson, J.K., Goodrum, P.E., Tyndall, K.H., Cox, L.A., Khatami, M., Morales-Montor, J., Schoeny, R.S., Seed, J.G., Tyagi, R.K. and Kirman, C.R., 2023. Weight of evidence evaluation for chemical-induced immunotoxicity for PFOA and PFOS: findings from an independent panel of experts. Critical Reviews in Toxicology, 53(1), pp.34-51.
Anderson, J.K., Brecher, R.W., Cousins, I.T., DeWitt, J., Fiedler, H., Kannan, K., Kirman, C.R., Lipscomb, J., Priestly, B., Schoeny, R. and Seed, J., 2022. Grouping of PFAS for human health risk assessment: Findings from an independent panel of experts. Regulatory Toxicology and Pharmacology. 134: 105-226
Fey, M.E., Goodrum, P.E., Razavi, N.R., Whipps, C.M., Fernando, S. and Anderson, J.K., 2022. Is Mixtures' Additivity Supported by Empirical Data? A Case Study of Developmental Toxicity of PFOS and 6:2 FTS in Wildtype Zebrafish Embryos. Toxics, 10(8), p.418.
Guelfo, J.L., Korzeniowski, S., Mills, M.A., Anderson, J., Anderson, R.H., Arblaster, J.A., Conder, J.M., Cousins, I.T., Dasu, K., Henry, B.J. and Lee, L.S., 2020. Environmental Sources, Chemistry, Fate and Transport of Per‐and Polyfluoroalkyl Substances: State of the Science, Key Knowledge Gaps, and Recommendations Presented at the August 2019 SETAC Focus Topic Meeting. Environmental Toxicology and Chemistr
Zodrow, J., Vedagiri, U., Sorell, T., McIntosh, L., Larson, E., Hall, L., ... & Anderson, J. (2022). PFAS Experts Symposium 2: PFAS Toxicology and Risk Assessment in 2021 — Contemporary issues in human and ecological risk assessment of PFAS. Remediation Journal, 32(1-2), 29-44.
Goodrum, P.E., Anderson, J.K., Luz, A.L. and Ansell, G.K., 2021. Application of a framework for grouping and mixtures toxicity assessment of PFAS: A closer examination of dose-additivity approaches. Toxicological Sciences, 179(2), pp.262-2
Mohr, T.K., DiGuiseppi, W.H., Hatton, J.W. and Anderson, J.K., 2020. Environmental investigation and remediation: 1, 4-dioxane and other solvent stabilizers. CRC Press.
Iwai, H., A.M. Hoberman, P.E. Goodrum, E. Mendelsohn, and J.K. Anderson. 2019. Addendum to Iwai and Hoberman (2014) — Reassessment of developmental toxicity of PFHxA in mice. Internat J Tox. 38(3):183-191.
Anderson, J.K., A.L. Luz, and P. Goodrum. 2019. Response to "Overgeneralization by Anderson et al. and Luz et al. regarding safety of fluorotelomer-base chemistry". Reg Tox Pharm. 105:100-10
Anderson, J.K., A.L. Luz, P. Goodrum, and J. Durda. 2019. Perfluorohexanoic acid toxicity, part II: application of human health toxicity value for risk characterization. Reg Tox Pharm. 103: 10-20.
Luz, A.L., J.K. Anderson, P. Goodrum, and J. Durda. 2019. Perfluorohexanoic acid toxicity, part I: development of a chronic human health toxicity value for use in risk assessment. Reg Tox Pharm. 103: 41-55.
Anderson, J.K., J. Wilhelm, and P. Goodrum. 2016. Emerging contaminants: An analysis of inconsistent U.S. regulations. Daily Environment Report. Bloomberg Bureau of National Affairs. August.
Anderson, R.H., G.C. Long, R.C. Porter, and J.K. Anderson. 2016. Occurrence of select perfluoroalkyl substances at U.S. Air Force aqueous film-forming foam release sites other than fire-training areas: field-validation of critical fate and transport properties. Chemosphere. 150:678 — 685.
Anderson, R.H., J.K. Anderson, and P.A. Bower. 2012. Co-occurrence of 1,4-dioxane with trichloroethylene in chlorinated solvent groundwater plumes at U.S. Air Force installations; fact or fiction. Integr Environ Assess Manag. 8(4):731 — 737.
Wang, N.C.Y., Q.J. Zhao, S.C. Wesselkamper, J.C. Lambert, D. Peterson, and J.K. Hess-Wilson. 2012. Application of computational toxicological tools and approaches in human health risk assessment I. A tiered surrogate approach. Regul Toxicol Pharmacol. 63:10 — 19.
Thomas, R.S., H.C. Clewell, B.C. Allen, S.C. Wesselkamper, N.Y. Wang, J.C. Lambert, J.K. Hess-Wilson, Q.J. Zhao, and M.E. Andersen. 2011. Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci. 120(1):194 — 205.
Mazur, C.S., J.F. Kenneke, J.K. Hess-Wilson, and J.L. Lipscomb. 2010. Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metab Dispos. 38(12):2232 — 2238.
Hess-Wilson, J.K. 2009. Bisphenol A may reduce the efficacy of androgen deprivation therapy in prostate cancer. Cancer Causes and Control. 20(7):1029 — 1037.
Shah, S., J.K. Hess-Wilson, S. Webb, H. Daly, S. Godoy-Tundidor, J. Kim, J. Boldison, Y. Daaka, and K.E. Knudsen. 2008. 2,2-Bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways. Mol Cancer Res. 6(9):1507 — 1520
Hess-Wilson, J.K., S.L. Webb, H.K. Daly, Y. K. Leung, J. Boldison, C.E.S. Comstock, M.A. Sartor, S.M. Ho, and K.E. Knudsen. 2007. Unique bisphenol A transcriptome in prostate cancer: novel effects on ERβ expression that correspond to AR mutation status. Environ Health Perspect. 115(11):1646 — 1653.
Sharma, A., E.S. Knudsen, J.K. Hess-Wilson, L.M. Morey, J. Barrera, and K.E. Knudsen. 2007. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res. 67(13):6192 — 6203.
Hess-Wilson, J.K., H.K. Daly, W.A. Zagorski, C.P. Montville, and K.E. Knudsen. 2006. Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res. 66(24):11998 — 12008.
Wetherill, Y.B., * J.K. Hess-Wilson,* C.E.S. Comstock, S.A. Shah, C.R. Buncher, L. Sallans, P.A. Limbach, S. Schwemberger, G.F. Babcock, and K.E. Knudsen. 2006. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther. 5(12):3181 — 3190. *Co-first authors
Hess-Wilson, J.K., J. Boldison, K.E. Weaver, and K.E. Knudsen. 2006. Xenoestrogen action in breast cancer: impact on ER-dependent transcription and mitogenesis. Breast Cancer Res Treat. 96(3):279 — 292
Hess-Wilson, J.K., and K.E. Knudsen. 2006. Endocrine disrupting compounds and prostate cancer. Cancer Lett. 241(1):1 — 12 — Invited review.
EPA Documents
USEPA. 2011. Volume I. EPA's re-analysis of key issues related to dioxin toxicity and response to NAS comments. Final review draft. EPA/600/R-10/038F. U.S. Environmental Protection Agency, Washington, DC. Contributing author.
USEPA. 2010. Provisional Peer-Reviewed Toxicity Values for 1,2-Dichloroethane (CASRN 107-06-2). EPA/690/R- 10/011F. Superfund Health Risk Technical Support Center, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Cincinnati, OH. Chemical Manager
USEPA. 2010. Recommended toxicity equivalence factors (TEFs) for human health risk assessments of 2,3,7,8- tetrachlorodibenzo-p-dioxin and dioxin-like compounds. EPA/100/R 10/005. U.S. Environmental Protection Agency, Risk Assessment Forum, Washington, DC. Coauthor.